Cited 6 time in
Conservative treatment for cutaneous fistula resulted from abscess formation in patients with tuberculous cervical lymphadenitis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Bo Hae | - |
| dc.contributor.author | Jeon, Yung Jin | - |
| dc.contributor.author | Jin, Young Ju | - |
| dc.contributor.author | Jeong, Woo-Jin | - |
| dc.contributor.author | Park, Sung Joon | - |
| dc.contributor.author | Ahn, Soon-Hyun | - |
| dc.date.accessioned | 2023-04-28T07:41:18Z | - |
| dc.date.available | 2023-04-28T07:41:18Z | - |
| dc.date.issued | 2018-10 | - |
| dc.identifier.issn | 0385-8146 | - |
| dc.identifier.issn | 1879-1476 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/9063 | - |
| dc.description.abstract | Objective: This study describes the clinical characteristics and course of conservative treatment using anti-Tb medication and dressing in patients with tuberculous cervical fistula resulting from abscess formation, and to investigate factors prognostic of dressing and treatment duration. Methods: The medical records of patients with tuberculous cervical lymphadenitis were reviewed, and 38 of these patients who presented with cutaneous fistula that resulted from abscess formation were included in the study. Results: The mean duration of dressing until fistula closure was 3.7 +/- 2.0 months (range 0.2-8.5), and the mean duration of treatment with anti-Tb medication was 10.6 +/- 2.6 months (range 6.0-16.0). Patients with concomitant Tb, beyond the cervical lymph nodes showed significantly prolonged duration of dressing (4.6 months vs. 3.2 months, p = 0.025) and anti-Tb medication (11.8 months vs. 9.8 months, p = 0.015). Conclusion: Our results indicate that about 3.7 months of dressing was required for fistula closure. Tuberculous cervical lymphadenitis patients with fistula who had Tb beyond the cervical lymph nodes could be expected to require dressing for 4.6 months and prolonged and anti-Tb medication treatment. (C) 2018 Elsevier B.V. All rights reserved. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ELSEVIER SCI LTD | - |
| dc.title | Conservative treatment for cutaneous fistula resulted from abscess formation in patients with tuberculous cervical lymphadenitis | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.anl.2018.01.006 | - |
| dc.identifier.scopusid | 2-s2.0-85041584906 | - |
| dc.identifier.wosid | 000438662000025 | - |
| dc.identifier.bibliographicCitation | AURIS NASUS LARYNX, v.45, no.5, pp 1061 - 1065 | - |
| dc.citation.title | AURIS NASUS LARYNX | - |
| dc.citation.volume | 45 | - |
| dc.citation.number | 5 | - |
| dc.citation.startPage | 1061 | - |
| dc.citation.endPage | 1065 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Otorhinolaryngology | - |
| dc.relation.journalWebOfScienceCategory | Otorhinolaryngology | - |
| dc.subject.keywordPlus | LYMPHADENOPATHY | - |
| dc.subject.keywordPlus | CHEMOTHERAPY | - |
| dc.subject.keywordPlus | GUIDELINES | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
| dc.subject.keywordPlus | DIAGNOSIS | - |
| dc.subject.keywordAuthor | Tuberculosis | - |
| dc.subject.keywordAuthor | Lymphadenitis | - |
| dc.subject.keywordAuthor | Cutaneous fistula | - |
| dc.subject.keywordAuthor | Abscess | - |
| dc.subject.keywordAuthor | Conservative | - |
| dc.subject.keywordAuthor | Treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
